Immunogenicity dynamics and covariate effects after satralizumab administration predicted with a hidden Markov model
CPT: Pharmacometrics & Systems Pharmacology · 2024
DOI: 10.1002/psp4.13230 ↗Kurz gefasst
Fachartikel in der Zeitschrift CPT: Pharmacometrics & Systems Pharmacology, 2024. Verfasst von Rory Leisegang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Uppsala University, Uppsala, Sweden. Hauptthemen laut MEDLINE: Markov Chains, Neuromyelitis Optica. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Immunogenicity is the propensity of a therapeutic protein to generate an immune response to itself. While reporting of antidrug antibodies (ADAs) is increasing, model‐based analysis of such data is seldom performed. Model‐based characterization of factors affecting the emergence and dissipation of ADAs may inform drug development and/or improve understanding in clinical practice. This analysis aimed to predict ADA dynamics, including the potential influence of individual covariates, following subcutaneous satralizumab administration. Satralizumab is a humanized IgG2 monoclonal recycling IL‐6 receptor antagonist antibody approved for treating neuromyelitis optica spectrum disorder (NMOSD). Longitudinal pharmacokinetic (PK) and ADA data from 154 NMOSD patients in two pivotal Phase 3 studies (NCT02028884, NCT02073279) and PK data from one Phase 1 study (SA‐001JP) in 72 healthy volunteers were available for this analysis. An existing population PK model was adapted to derive steady‐state concentration without ADA for each patient. A mixed hidden Markov model (mHMM) was developed whereby three different states were identified: one absorbing Markov state for non‐ADA developer, and two dynamic and inter‐connected Markov states—transient ADA negative and positive. Satralizumab exposure and body mass index impacted transition probabilities and, therefore, the likelihood of developing ADAs. In conclusion, the mHMM model was able to describe the time course of ADA development and identify patterns of ADA development in NMOSD patients following treatment with satralizumab, which may allow for the formulation of strategies to reduce the emergence or limit the impact of ADA in the clinical setting.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, Uppsala University, Uppsala, Sweden.
- Roche Pharma Research and Early Development, Pharmaceutical Sciences, Roche Innovation Center Basel, Basel, Switzerland.
- Roche Products Ltd, Welwyn, UK.
- Chugai Pharmaceutical Co., Tokyo, Japan.
ORCID-Profile: Rory Leisegang, Hanna E Silber Baumann, Siân Lennon-Chrimes, Hajime Ito, Kazuhiro Miya, Jean-Christophe Genin, Elodie L Plan
Zitieren
APA
Leisegang, R., Silber Baumann, H. E., Lennon-Chrimes, S., Ito, H., Miya, K., Genin, J. C., & Plan, E. L. (2024). Immunogenicity dynamics and covariate effects after satralizumab administration predicted with a hidden Markov model. CPT: Pharmacometrics & Systems Pharmacology. https://doi.org/10.1002/psp4.13230
Vancouver
Leisegang R, Silber Baumann HE, Lennon-Chrimes S, Ito H, Miya K, Genin JC, et al. Immunogenicity dynamics and covariate effects after satralizumab administration predicted with a hidden Markov model. CPT: Pharmacometrics & Systems Pharmacology. 2024. doi:10.1002/psp4.13230
BibTeX
@article{Leisegang2024,
author = {Leisegang, Rory and Silber Baumann, Hanna E and Lennon-Chrimes, Siân and Ito, Hajime and Miya, Kazuhiro and Genin, Jean-Christophe and Plan, Elodie L},
title = {Immunogenicity dynamics and covariate effects after satralizumab administration predicted with a hidden Markov model},
journal = {CPT: Pharmacometrics & Systems Pharmacology},
year = {2024},
doi = {10.1002/psp4.13230}
}
EUVIMED